

Australian Clinical Labs Limited

ABN 62 006 823 089
Registered Office:
1868-1892 Dandenong Road
Clayton VIC 3168
Australia

clinicallabs.com.au

Thursday 4 August 2022

ACL FY22 FINANCIAL RESULTS INVESTOR WEBINAR

Australian Clinical Labs Limited (ASX: ACL) (ACL or Company) is planning to release its financial and operating results for the financial year ended 30 June 2022, on Wednesday, 10 August 2022.

ACL Chief Executive Officer and Executive Director, Melinda McGrath, and Chief Financial Officer, James Davison, will host an investor webinar via Zoom at 11am AEST on that day.

Participants will need to register in advance for the webinar by clicking on the link below.

Registered participants will receive a confirmation email containing information on how to join the webinar.

Click here to register for the webinar:

https://clinicallabs-au.zoom.us/webinar/register/WN_C_W_JOVuRTy_82IWCywc-g

A recording of the webinar will be available on the Investors section of the website at [Home | Australian Clinical Labs](#).

– ENDS –

This announcement was authorised for release to ASX by the Eleanor Padman, Company Secretary of ACL. For further information regarding this announcement, please contact:

Company Secretary

Eleanor Padman
Company Secretary
Email: epadman@padmanadvisory.com.au
Phone: +61 (0) 422 002 918

About Australian Clinical Labs

ACL is a leading Australian private provider of pathology services. Our NATA accredited laboratories perform a diverse range of pathology tests each year for a range of clients including doctors, specialists, patients, hospitals and corporate clients. ACL is one of the largest private hospital pathology businesses nationally. ACL is focused on its mission of combining talented people, and medical and scientific leadership, with innovative thinking and technologies to empower decision making that saves and improves patients' lives.